Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017
15% Year-Over-Year Growth, with Sales Set to More than Double by 2022
Kite Earns Patent for Method to Increase Efficacy of CAR-T
Company Snags Rights for Use of Optimal Preconditioning Regimen
Biomaterials Could Extend the Success of Immunotherapies
A New Review Paper Encourages Clinicians to Pull Ideas from the Desks of Engineers
Unlucky 13: Top Clinical Trial Failures of 2017
In Missing Their Primary Endpoints, These Drugs Sparked Layoffs, Losses, and a CEO Resignation
For full access to this article login to GEN Select now.
Synthetic Bio Not Yet Ready for the Market
Lab-Designed Calls and Pathways Take Genetic and Metabolic Engineering to Next Level
- In May of this year, the J. Craig Venter Institute (JCVI) announced it had created the first fully synthetic, self-replicating bacterial cell ( Mycoplasma nycoides JCVI-syn1.0). While this proof-of-concept demonstration of an “artificial life form” might raise justifiable fears about the dangers of unregulated or nefarious synthetic biology efforts, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.